PRKCD and renal carcinoma: We have recently shown that CNI treatment can activate H-Ras, and can also induce the phosphorylation of its downstream targets, PKC-ζ and PKC-δ; and promotes the overexpression of VEGF in human renal cancer cells [22], [23].